Laboratory of Therapeutic Vaccines, I. I. Metchnikov Research Institute for Vaccines and Serum, Russian Academy of Medical Sciences , Moscow , Russia.
Front Immunol. 2014 Mar 5;5:89. doi: 10.3389/fimmu.2014.00089. eCollection 2014.
Tγδ and B1 lymphocytes are essential components of the mucosal immune system, activated directly by different bacterial and viral ligands without additional costimulatory signals and preprocessing of other immune effectors. This ability enables the immune system to provide rapid protection against pathogens and contributes to the decoding mechanism of the sensitizing activity of mucosal antigens. The early interaction of these cells results in the production of antibodies of immunoglobulin M (IgM) and IgA isotypes, but not immunoglobulin E (IgE). We studied the subcutaneous, intranasal, and oral delivery as three major routes of potential entry for antigens of opportunistic microorganisms, using the immunomodulator Immunovac-VP-4, which is able to activate Tγδ and B1 lymphocytes. The subcutaneous and intranasal routes produced a significant increase of these cells in lymph nodes associated with the nasal cavity (NALT) and in those associated with bronchial tissue (BALT). The oral route significantly increased levels of these cells in the spleen, in NALT, BALT, and in nodes associated with the gut (GALT). We found that mucosal application of Immunovac-VP-4, which contains antigens of conditionally pathogenic microorganisms, in conjunction with the activation of Tγδ and B1, induces adaptive immune mechanisms not only in the lymphoid formations associated with the respiratory system and with GALT, but also in the spleen [increased expression of cluster of differentiation 3 (CD3), CD4, CD8, CD19, and CD25]. This indicates that there is migration of lymphoid cells from the regional lymph nodes and mucosal lymphoid tissues via the lymph and blood to distant organs, resulting in lymphoid development, and both local and systemic immunity. Mucosal application of Immunovac-VP-4 in mice potentiates the cytotoxic activity of NK cells in the NALT, BALT, and GALT. The highest cytotoxicity was observed in cells, derived from lymphoid tissue of the intestine after oral immunization. Although we found that cytokine production was increased by all three immunization routes, it was most intensive after subcutaneous injection. Our findings confirm that there is an intensive exchange of lymphocytes not only between lymphoid formations in the mucous membranes of the respiratory tract and of GALT, but also with the spleen, which means that if effective mucosal vaccines are developed, they can induce both local and systemic immunity.
Tγδ 和 B1 淋巴细胞是黏膜免疫系统的重要组成部分,它们直接被不同的细菌和病毒配体激活,而无需其他共刺激信号和其他免疫效应物的预处理。这种能力使免疫系统能够迅速提供针对病原体的保护,并有助于解释黏膜抗原致敏活性的解码机制。这些细胞的早期相互作用导致产生免疫球蛋白 M(IgM)和 IgA 同种型的抗体,但不产生免疫球蛋白 E(IgE)。我们研究了三种主要的潜在抗原进入途径,即皮下、鼻内和口服途径,使用免疫调节剂 Immunovac-VP-4,它能够激活 Tγδ 和 B1 淋巴细胞。皮下和鼻内途径使鼻腔相关淋巴结(NALT)和支气管组织相关淋巴结(BALT)中这些细胞的数量显著增加。口服途径使这些细胞在脾脏、NALT、BALT 和与肠道相关的淋巴结(GALT)中的水平显著增加。我们发现,黏膜应用包含条件致病微生物抗原的 Immunovac-VP-4,结合 Tγδ 和 B1 的激活,不仅在与呼吸系统和 GALT 相关的淋巴组织中,而且在脾脏中诱导适应性免疫机制[增加了分化群 3(CD3)、CD4、CD8、CD19 和 CD25 的表达]。这表明,淋巴细胞从区域性淋巴结和黏膜淋巴组织通过淋巴和血液迁移到远处器官,导致淋巴组织发育和局部及全身免疫。在小鼠中黏膜应用 Immunovac-VP-4 增强了 NALT、BALT 和 GALT 中 NK 细胞的细胞毒性活性。在口服免疫后从肠道淋巴组织中获得的细胞中观察到最高的细胞毒性。虽然我们发现所有三种免疫途径都增加了细胞因子的产生,但皮下注射后最为明显。我们的研究结果证实,不仅在呼吸道和 GALT 的黏膜淋巴组织之间,而且在与脾脏之间,淋巴细胞之间存在密集的交换,这意味着如果开发出有效的黏膜疫苗,它们可以诱导局部和全身免疫。